According to HLB Pep on the 17th, the new president will be responsible for expanding overseas operations and establishing production and quality systems. He plans to focus on upgrading the operational systems at the Osong and Jangseong plants to meet global regulatory standards, such as those of the U.S. Food and Drug Administration (FDA).
HLB Pep plans to strengthen its production and quality capabilities while increasing collaboration with global pharmaceutical companies and securing new clients. Through these efforts, the company aims to expand exports of peptide active pharmaceutical ingredients (APIs) and develop the Osong plant into a production hub capable of serving the global market.
The newly appointed CEO majored in molecular and cellular biology at the University of California, Berkeley (UC Berkeley) and subsequently worked in quality operations at Bristol-Myers Squibb (BMS). He later joined SAMSUNG BIOLOGICS as a founding member, where he worked for approximately 11 years, overseeing the establishment of the bulk drug substance production organization and serving as head of the finished drug product (DP) business division.
After serving on the New Growth Team at Lotte Corporation, he was appointed as the first CEO of Lotte Biologics in 2022. At that time, he spearheaded the acquisition of BMS’s Syracuse, New York, plant, leading the launch of Lotte Biologics and securing its production infrastructure.
HLB Pep plans to leverage the new CEO’s experience working at global pharmaceutical companies and his expertise in operating production facilities to expand its overseas business. The company is prioritizing meeting the quality standards required by overseas clients and building trust as a reliable supply partner.
Building on the new CEO’s experience in the global pharmaceutical and biotech industries, HLB Pep intends to focus on securing overseas clients and establishing world-class production and quality systems.
In his inaugural address to employees, the new CEO stated, “HLB Pep possesses the technological expertise and production capabilities it has built up in the field of peptide active pharmaceutical ingredients (APIs),” adding, “We will solidify a quality system that meets global regulatory standards and build trust with overseas customers to establish ourselves as a supply partner for APIs to global pharmaceutical companies.”